



D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of.:

Anthony FUTERMAN, et al

Serial No.: 10/552,287

Filed: January 4, 2007

For: GAUCHER DISEASE DRUGS
AND METHODS OF
IDENTIFYING SAME§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1656

Attorney Docket: 30227

Mail Stop: Assignment Services Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED NOTICE OF RECORDATION OF ASSIGNMENT

Sir,

Attached hereto are copies of the Notice of Recordation of Assignment and the papers upon which the same was issued.

Please note that the Title, namely "**GAUCHER DISEASE DRUGS AND METHODS OF IDENTIFYING SAME**", and Filing Date, namely "**January 4, 2007**", were both omitted from the Notice of Recordation of Assignment.

The Title appears on the attached executed Assignment. The official Filing Receipt, indicating both the Title and Filing Date, is also attached herewith.

Kindly correct the above errors and issue a Corrected Notice of Recordation of Assignment.

Respectfully submitted,

Martin D. Moynihan
Registration No. 40,338

Date: May 1, 2007



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCTOBER 25, 2006

MARTIN D. MOYNIHAN
P.O. BOX 16446
PRTSI, INC.
ARLINGTON, VA 22215

PTAS

500169127A

500169127A



**UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT**

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 10/25/2006

REEL/FRAME: 018430/0860
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).
DOCKET NUMBER: 30227

ASSIGNOR:

FUTERMAN, ANTHONY

DOC DATE: 11/24/2005

ASSIGNOR:

SUSSMAN, JOEL L.

DOC DATE: 10/04/2005

ASSIGNOR:

SILMAN, ISRAEL

DOC DATE: 11/03/2005

ASSIGNOR:

HAREL, MICHAL

DOC DATE: 11/16/2005

ASSIGNOR:

DVIR, HAY

DOC DATE: 11/01/2005

018430/0860 PAGE 2

ASSIGNOR:
TOKER, LILLY

DOC DATE: 11/22/2005

ASSIGNOR:
ADAMSKY, SWETLANA

DOC DATE: 11/27/2005

ASSIGNEE:
YEDA RESEARCH AND DEVELOPMENT CO.
LTD.
P.O. BOX 95
AT THE WEIZMANN INSTITUTE OF
SCIENCE
RECHOVOT, ISRAEL 76100

SERIAL NUMBER: 10552287
PATENT NUMBER:
TITLE:

FILING DATE: ← January 4, 2007
ISSUE DATE:

← GAUCHER DISEASE DRUGS AND METHODS OF IDENTIFYING SAME

ASSIGNMENT SERVICES BRANCH
PUBLIC RECORDS DIVISION



30227

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned:

Anthony FUTERMAN	12 Neve Metz, The Weizmann Institute of Science, 76100 Rehovot, Israel
Joel, L. SUSSMAN	42 HaNassi HaRishon Street, 76302 Rehovot, Israel
Israel SILMAN	54 HaNassi HaRishon Street, 76302 Rehovot, Israel
Michal HAREL	2 HaParag Street, 76568 Rehovot, Israel
Hay DVIR	67/9 Kalman Magen Street, 99532 Beit Shemesh, Israel
Lilly TOKER	41 Dubnov Street, 76406 Rehovot, Israel
Swetlana ADAMSKY	50 Hershenzon Street, 76484 Rehovot, Israel

hereby sell(s), assign(s) and transfer(s) to:

Yeda Research And Development Co. Ltd.
at the Weizmann Institute of Science
P.O. Box 95
76100 Rehovot
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

GAUCHER DISEASE DRUGS AND METHODS OF IDENTIFYING SAME

described and claimed in the following Patent Application:

Entry into National Phase in the USA of PCT Patent Application
No. PCT/IL2004/000335, international filing date 18 April 2004
identified as Attorney Docket No. 30227

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the priority rights under International Conventions, and the Letters Patent which may be granted thereon:

covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

<u>A.F.</u> Anthony FUTERMAN Date: <u>24/11/05</u>	Joel, L. SUSSMAN Date: _____	Israel SILMAN Date: _____	Michal HAREL Date: _____
Hay DVIR Date: _____	Lilly TOKER Date: _____	<u>[Signature]</u> Swetlana ADAMSKY Date: <u>27.11.05</u>	

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned:

Anthony FUTERMAN	12 Neve Metz, The Weizmann Institute of Science, 76100 Rehovot, Israel
Joel, L. SUSSMAN	42 HaNassi HaRishon Street, 76302 Rehovot, Israel
Israel SILMAN	54 HaNassi HaRishon Street, 76302 Rehovot, Israel
Michal HAREL	2 HaParag Street, 76568 Rehovot, Israel
Hay DVIR	67/9 Kalman Magen Street, 99532 Beit Shemesh, Israel
Lilly TOKER	41 Dubnov Street, 76406 Rehovot, Israel
Swetlana ADAMSKY	50 Hershenzon Street, 76484 Rehovot, Israel

hereby sell(s), assign(s) and transfer(s) to:

Yeda Research And Development Co. Ltd.
at the Weizmann Institute of Science
P.O. Box 95
76100 Rehovot
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

GAUCHER DISEASE DRUGS AND METHODS OF IDENTIFYING SAME

described and claimed in the following Patent Application:

Entry into National Phase in the USA of PCT Patent Application
No. PCT/IL2004/000335, international filing date 18 April 2004
Identified as Attorney Docket No. 30227

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the priority rights under International Conventions, and the Letters Patent which may be granted thereon:

covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

Anthony FUTERMAN	Joel, L. SUSSMAN	Israel SILMAN	Michal HAREL
Date: _____	Date: <u>14 OCT 2004</u>	Date: _____	Date: _____
Hay DVIR	Lilly TOKER	Swetlana ADAMSKY	
Date: _____	Date: _____	Date: _____	

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned:

Anthony FUTERMAN	12 Neve Metz, The Weizmann Institute of Science, 76100 Rehovot, Israel
Joel L. SUSSMAN	42 HaNassi HaRishon Street, 76302 Rehovot, Israel
Israel SILMAN	54 HaNassi HaRishon Street, 76302 Rehovot, Israel
Michal HAREL	2 HaParag Street, 76368 Rehovot, Israel
Hay DVIR	67/9 Kalman Magon Street, 99532 Beit Shemesh, Israel
Lilly TOKER	41 Dubnov Street, 76406 Rehovot, Israel
Swetlana ADAMSKY	50 Hershenzon Street, 76484 Rehovot, Israel

heroby sell(s), assign(s) and transfer(s) to:

Yeda Research And Development Co. Ltd.
at the Weizmann Institute of Science
P.O. Box 95
76100 Rehovot
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

GAUCHER DISEASE DRUGS AND METHODS OF IDENTIFYING SAME

described and claimed in the following Patent Application:

Entry into National Phase in the USA of PCT Patent Application
No. PCT/IL2004/000335, International filing date 18 April 2004
identified as Attorney Docket No. 30227

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the priority rights under International Conventions, and the Letters Patent which may be granted thereon;


covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

Anthony FUTERMAN
Date: _____

Joel L. SUSSMAN
Date: _____


Israel SILMAN
Date: 03.4.05

Michal HAREL
Date: _____

Hay DVIR
Date: _____

Lilly TOKER
Date: _____

Swetlana ADAMSKY
Date: _____

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned:

Anthony FUTERMAN	12 Neve Metz, The Weizmann Institute of Science, 76100 Rehovot, Israel
Joel, L. SUSSMAN	42 HaNassi HaRishon Street, 76302 Rehovot, Israel
Israel SILMAN	54 HaNassi HaRishon Street, 76302 Rehovot, Israel
Michal HAREL	2 HaParag Street, 76568 Rehovot, Israel
Hay DVIR	67/9 Kalman Magen Street, 99532 Beit Shemesh, Israel
Lilly TOKER	41 Dubnov Street, 76406 Rehovot, Israel
Swetlana ADAMSKY	50 Hershenzon Street, 76484 Rehovot, Israel

heroby sell(s), assign(s) and transfer(s) to:

Yeda Research And Development Co. Ltd.
at the Weizmann Institute of Science
P.O. Box 95
76100 Rehovot
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

GAUCHER DISEASE DRUGS AND METHODS OF IDENTIFYING SAME

described and claimed in the following Patent Application:

Entry Into National Phase in the USA of PCT Patent Application
No. PCT/IL2004/000335, international filing date 18 April 2004
identified as Attorney Docket No. 30227

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the priority rights under International Conventions, and the Letters Patent which may be granted thereon:

covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

Anthony FUTERMAN
Date: _____

Joel, L. SUSSMAN
Date: _____

Israel SILMAN
Date: _____

Michal Harel
Michal HAREL
Date: 16.11.05

Hay DVIR
Date: _____

Lilly TOKER
Date: _____

Swetlana ADAMSKY
Date: _____

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned:

Anthony FUTERMAN	12 Neve Metz, The Weizmann Institute of Science, 76100 Rehovot, Israel
Joel, L. SUSSMAN	42 HaNassi HaRishon Street, 76302 Rehovot, Israel
Israel SILMAN	54 HaNassi HaRishon Street, 76302 Rehovot, Israel
Michal HAREL	2 HaParag Street, 76568 Rehovot, Israel
Hay DVIR	67/9 Kalman Magen Street, 99532 Beit Shemesh, Israel
Lilly TOKER	41 Dubnov Street, 76406 Rehovot, Israel
Swetlana ADAMSKY	50 Hershenzon Street, 76484 Rehovot, Israel

hereby sell(s), assign(s) and transfer(s) to:

Yeda Research And Development Co. Ltd.
at the Weizmann Institute of Science
P.O. Box 95
76100 Rehovot
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

GAUCHER DISEASE DRUGS AND METHODS OF IDENTIFYING SAME

described and claimed in the following Patent Application:

Entry into National Phase in the USA of PCT Patent Application
No. PCT/IL2004/000335, international filing date 18 April 2004
identified as Attorney Docket No. 30227

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the priority rights under International Conventions, and the Letters Patent which may be granted thereon:

covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

Anthony FUTERMAN
Date: _____

Joel, L. SUSSMAN
Date: _____

Israel SILMAN
Date: _____

Michal HAREL
Date: _____

Hay DVIR
Date: 11.1.05

Lilly TOKER
Date: _____

Swetlana ADAMSKY
Date: _____

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned:

Anthony FUTERMAN	12 Neve Metz, The Weizmann Institute of Science, 76100 Rehovot, Israel
Joel, L. SUSSMAN	42 HaNassi HaRishon Street, 76302 Rehovot, Israel
Israel SILMAN	54 HaNassi HaRishon Street, 76302 Rehovot, Israel
Michal HAREL	2 HaParag Street, 76568 Rehovot, Israel
Hay DVIR	67/9 Kalman Magen Street, 99532 Beit Shemesh, Israel
Lilly TOKER	41 Dubnov Street, 76406 Rehovot, Israel
Swetlana ADAMSKY	50 Hershenzon Street, 76484 Rehovot, Israel

hereby sell(s), assign(s) and transfer(s) to:

Yeda Research And Development Co. Ltd.
at the Weizmann Institute of Science
P.O. Box 95
76100 Rehovot
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

GAUCHER DISEASE DRUGS AND METHODS OF IDENTIFYING SAME

described and claimed in the following Patent Application:

Entry into National Phase in the USA of PCT Patent Application
No. PCT/IL2004/000335, international filing date 18 April 2004
identified as Attorney Docket No. 30227

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the priority rights under International Conventions, and the Letters Patent which may be granted thereon:

covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

Anthony FUTERMAN	Joel, L. SUSSMAN	Israel SILMAN	Michal HAREL
Date: _____	Date: _____	Date: _____	Date: _____
Hay DVIR	Lilly TOKER	Swetlana ADAMSKY	
Date: _____	Date: <u>22.11.05</u>	Date: _____	



COPY

Page 1 of 3



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLMS	IND CLMS
10/552,287	01/04/2007	1656	1440	30227	37	7

Martin Moynihan
Prtsi Inc
P O Box 16446
Arlington, VA 22215

CONFIRMATION NO. 6293

FILING RECEIPT



OC000000023301308

Date Mailed: 04/12/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Anthony Futerman, Rehovot, ISRAEL;
Joel L. Sussman, Rehovot, ISRAEL;
Israel Silman, Rehovot, ISRAEL;
Michal Harel, Rehovot, ISRAEL;
Hay Dvir, Beit Shemesh, ISRAEL;
Lilly Toker, Rehovot, ISRAEL;
Swetlana Adamsky, Rehovot, ISRAEL;

Power of Attorney:

Martin Moynihan--40338

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/IL04/00335 04/18/2004
which claims benefit of 60/463,049 04/16/2003

Foreign Applications

ISRAEL 156273 06/02/2003

If Required, Foreign Filing License Granted: 04/09/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/552,287**

Projected Publication Date: 07/19/2007



Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Gaucher disease drugs and methods of identifying same

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING

LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/552,287	Anthony Futerman	30227

Martin Moynihan
Prtsi Inc
P O Box 16446
Arlington, VA 22215

COPY

INTERNATIONAL APPLICATION NO.	
PCT/IL04/00335	
I.A. FILING DATE	PRIORITY DATE
04/18/2004	04/16/2003

CONFIRMATION NO. 6293

371 ACCEPTANCE LETTER



OC000000023301309

Date Mailed: 04/12/2007

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

<u>01/04/2007</u>	<u>01/04/2007</u>
DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS	DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. **THE DATE APPEARING ON THE FILING RECEIPT AS THE " FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE.** The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Indication of Small Entity Status
- Copy of the International Application filed on 10/04/2005
- Copy of the International Search Report filed on 10/04/2005
- Preliminary Amendments filed on 10/04/2005
- Biochemical Sequence Diskette filed on 01/04/2007
- Oath or Declaration filed on 01/04/2007
- Biochemical Sequence Listing filed on 10/04/2005
- Request for Immediate Examination filed on 10/04/2005
- U.S. Basic National Fees filed on 10/04/2005
- Priority Documents filed on 10/04/2005
- Specification filed on 10/04/2005

- Claims filed on 10/04/2005
- Abstracts filed on 10/04/2005
- Drawings filed on 10/04/2005
- Paper nucleotide sequence listings filed on 10/04/2005

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

FRANCINE YOUNG

Telephone: (703) 308-9140 EXT 215

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/903 (371 Acceptance Notice)